

Wockhardt's COVID-19 vaccination contract with UK extends to Aug 2022

10 February 2021 | News

This expands the original agreement from 18 to 24 months



Wockhardt, the global pharmaceutical and biotechnology major, has announced that it has been awarded a six-month extension of its agreement with the UK Government to fill-finish COVID-19 vaccines.

This expands the original agreement from 18 to 24 months ie, until August 2022 and the manufacturing will continue to be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales.

Liz Truss, UK International Trade Secretary on her visit to Mumbai as part of a drive to improve business links between the UK and India announced the extension, said, "This is a brilliant bit of news for the UK and people of Wrexham. It brings important investment to the local area, bringing jobs and security to the community as we battle this awful pandemic. Wockhardt's investment shows the strength of our trading ties with India which is a further boost to our already-strong vaccine supply as we build back stronger from coronavirus."

Dr Habil Khorakiwala, Founder Chairman, Wockhardt Group emphasised, "We are happy to extend our collaboration with the UK Government to make vaccines available and the arrangement brings in a huge sense of purpose and pride, it upholds our ongoing global commitment to fight against an unprecedented pandemic."